1 INTRODUCTION Despite advances in targeted and immune therapies, cytotoxic chemotherapy remains the gold standard, first line treatment for many common cancers including breast cancer, colorectal cancer and diffuse large B-cell lymphoma (DLBCL).1 These anticancer agents are characterised by a narrow therapeutic index and large interindividual pharmacokinetic variability.